• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Randy Osborne

Randy Osborne

Articles

ARTICLES

Finding their way in BTK: Aptose, others research resistance-beating ploys

April 4, 2019
By Randy Osborne
With the recent granting of the IND for trials to begin with CG-806 in the hands of Aptose Biosciences Inc., the rich and busy field of Bruton's tyrosine kinase (BTK) inhibitors may be set to further evolve.
Read More

Tre's company in NLRP3? It's Novartis, shelling out potential $1.5B+ for IFM

April 2, 2019
By Randy Osborne
Less than a week after starting the phase I trial with its lead NLRP3 antagonist, IFM-2427, Boston-based IFM Therapeutics LLC chalked up a contract potentially worth more than $1.5 billion for anti-inflammatory therapies with Novartis AG, which brings aboard the whole portfolio in the class via the buyout of subsidiary IFM Tre.
Read More

Merck KGaA, Circassia score FDA approvals in MS and COPD maintenance

April 2, 2019
By Randy Osborne
The FDA ended last week and started this one with drug approvals, clearing Darmstadt, Germany-based Merck KGaA's Mavenclad (cladribine) tablets for relapsing multiple sclerosis (MS) in adults – with a label that includes relapsing-remitting disease as well as active secondary progressive MS (SPMS) – and followed with marketing clearance for Duaklir, a fixed-dose inhaled combination from Circassia Pharmaceuticals Inc., of Oxford, U.K., that pairs long-acting muscarinic antagonist (LAMA) aclidinium bromide with long-acting beta agonist (LABA) formoterol fumarate for chronic obstructive pulmonary disease (COPD) maintenance.
Read More

Fistula fizzle puts Proteon on skids; vonipanitase bid uncertain, maybe curtains

March 29, 2019
By Randy Osborne
"We got it wrong," mourned Maxim analyst Jason McCarthy after Waltham, Mass.-based Proteon Therapeutics Inc. disclosed results from the phase III trial called Patency-2, a 603-patient experiment with vonapanitase, made up of recombinant human elastase, in patients with chronic kidney disease (CKD) undergoing creation of radiocephalic (wrist) fistulas for vascular access in hemodialysis.
Read More

Big 'diff' separating drugs from FMT; FDA expected to offer guidance clarity

March 28, 2019
By Randy Osborne
With further FDA guidance yet to come on how fecal microbiota transplants (FMTs) to treat Clostridium difficile (C. diff) infections will be regulated, investors continue to weigh the odds of drugs vs. the controversial but popular therapy.
Read More

Secondary offering in MS: Novartis' Mayzent cleared with cross-spectrum label

March 28, 2019
By Randy Osborne
Trial designer and steering committee member Bruce Cree told BioWorld that the FDA made "a very wise decision" in assigning the broad label to Novartis AG's oral sphingosine 1-phosphate (S1P) receptor modulator Mayzent (siponimod) in multiple sclerosis (MS), "covering the continuum from clinically isolated syndrome all the way into active secondary progressive MS [SPMS]."
Read More

Lexicon, Sanofi hit with CRL on Zynquista; Recro with IV meloxicam gets one, too

March 25, 2019
By Randy Osborne
On the PDUFA date for Zynquista (sotagliflozin), the FDA delivered a complete response letter (CRL) to Lexicon Pharmaceuticals Inc. and partner Sanofi SA related to the NDA for the type 1 diabetes therapy, an oral dual inhibitor of sodium glucose transporter (SGLT) 1 and 2 that was previously known as LX-4211. Recro Pharma Inc. also found a CRL in its mailbox, related to the NDA for intravenous (I.V.) meloxicam for the management of moderate to severe pain.
Read More

On schedule: PDUFA date hit, DEA to deliberate Jazz sleep drug listing position

March 22, 2019
By Randy Osborne
Now that Dublin-based Jazz Pharmaceuticals plc has gained FDA marketing clearance for Sunosi (solriamfetol), investors are waiting to see how the DEA will schedule the compound, and J.P. Morgan analyst Jessica Fye said her "base case for DEA scheduling for Sunosi is [schedule] IV." The human abuse liability study compared the drug to phentermine and Sunosi "appeared less 'likable' than that schedule IV agent (note that [methylphenidate and d-amphetamine] are schedule II given their higher potential for abuse/dependence)," Fye wrote in a report.
Read More

Steal Magnolia's? Sage win in PPD back-seats Marinus as I.V.-to-oral bid ongoing

March 21, 2019
By Randy Osborne
The widely expected approval of Sage Therapeutics Inc.'s 60-hour intravenous (I.V.) Zulresso (brexanolone) in postpartum depression (PPD) opens the marketing door to the first therapy approved in the indication and raised investor hopes for Marinus Therapeutics Inc., developing a similar PPD therapy in I.V.-to-oral form as well as an all-oral version.
Read More

Some eye Urovant aslant, weigh Myrbetriq metrics; 'misplaced' ideas in OAB?

March 20, 2019
By Randy Osborne
Urovant Sciences Ltd.'s favorable top-line data from the phase III study called Empowur with vibegron in adults with overactive bladder (OAB) did not bring the stock-boosting effect that some might have expected, as doubters fretted that the once-daily beta-3 adrenergic receptor agonist did not perform well enough relative to generic tolterodine, even though – as J.P. Morgan analyst Eric Joseph pointed out – the latter was not meant for a head-to-head comparison.
Read More
View All Articles by Randy Osborne

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 28, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 28, 2025.
  • Boston Scientific Acurate Prime Aortic Valve System

    In TAVR setback, Boston Sci pulls plug on Acurate valves

    BioWorld MedTech
    Boston Scientific Corp. reported the latest setback in its transcatheter aortic valve replacement (TAVR) aspirations with the news that it is officially...
  • 3d rendering of bispecific antibodies

    Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody

    BioWorld
    Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 27, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe